Traditional lumbar fusion is a type of spinal surgery in which two or more vertebrae, typically in the lower back, are fused together with bone grafts and instrumentation. The aim of the procedure is to stabilize the spine and reduce or eliminate back pain. In some cases, the procedure can also help with nerve-related symptoms, such as numbness or tingling. The fusion process begins with the patient undergoing an imaging study—such as an X-ray or MRI—to map out the area of the spine where the fusion will be done. During lumbar fusion, the surgeon will make an incision in the back to access the spine. They will then remove the discs or other structures between the vertebrae, as well as any spurs, deformities, or damaged cartilage. Once the debris is cleared, a bone graft will be placed on the back of the spine, and instrumentation (usually in the form of screws, rods, plates, cages, or wires) is added to hold the vertebrae together. Over the course of several months, the bone graft will bind to the vertebrae and create a permanent fusion. During this time, the patient is usually advised to participate in a supervised rehabilitation program (physical therapy and exercises) to aid with recovery. Traditional lumbar fusion is a reliable option for relieving lower back pain and restoring spinal stability, and, in most cases, it can offer a significant improvement in quality of life. The procedure is generally recommended for those with severe pain, instability, or spinal deformity. There are, however, potential risks associated with the procedure, including infection, nerve damage, and ongoing pain. Patients considering lumbar fusion should speak to their doctor to learn more about the potential benefits and risks associated with the procedure.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States